Abstract
Background Data on the long-term survival and incidence of disability milestones after subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD) is limited.
Objectives To estimate mortality among PD patients 8 years after STN-DBS and to quantify the frequency /time-to-development of disability milestones (falls, freezing, hallucinations, dementia, and institutionalization).
Methods A longitudinal retrospective study of patients submitted to STN-DBS between 2006-2012 was carried-out. For mortality, Cox proportional hazards regression analysis was performed. For disease milestones, competing risk analyses were performed and cumulative incidence functions calculated. Multivariable regression analysis in the presence of competing risks was performed based on the Gray’s test of sub-distribution hazards of cumulative incidence functions.
Results An overall mortality rate of 16% (mean 62.1 ± 21.3 months after surgery) was observed. Falls (73%) and freezing (47%) were both the earliest (40.4 ± 25.4 and 39.6 ± 28.4 months, respectively) and most frequently observed milestones. Dementia (34%) and hallucinations (32%) soon follow (56.2 ± 21.2 and mean 60.0 ± 20.7 months after surgery, respectively). Institutionalization occurred in 6% after 62.3 ± 22.0 months. Higher ADL scores in the OFF state and higher age at surgery were associated with falls, freezing, dementia and institutionalization.
Conclusions Long-term mortality rate is low after STN-DBS, with STN-DBS patients developing the same disability milestones as non-DBS patients. Motor milestones occur first and at a higher frequency than cognitive ones. Milestones cluster together before death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fundacao para a Ciencia e Tecnologia (FCT) through a Ph.D. Scholarship (SFRH/BD/143797/2019) and Premio Joao Lobo Antunes by Santa Casa da Misericordia de Lisboa
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Local Ethical Committee (“Comissão de Ética do Centro Académico de Medicina de Lisboa – CAML”).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
